0
0
A new wave of weight-loss medications has revolutionized the treatment of obesity, offering unprecedented results for millions worldwide. Drugs like Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lilly’s Mounjaro, have surged in popularity due to their remarkable effectiveness in helping patients lose an average of 15% to 20% of their body weight during clinical trials.
These medications work by enhancing the action of glucagon-like peptide-1 (GLP-1), a hormone in the pancreas that regulates insulin secretion. Originally developed for diabetes management, GLP-1 drugs were found to significantly suppress appetite, making individuals feel fuller for longer periods and thus aiding in substantial weight loss.
Obesity experts now consider these drugs a historic breakthrough, especially as obesity affects nearly 900 million people globally. French endocrinologist Emmanuel Disse emphasized that these treatments “cover a major unmet need: obesity was one of the only chronic diseases for which there were few medications”. Previously, bariatric surgery was the primary option for those who did not respond to diet and exercise.
Despite their success, the drugs are not without limitations. Side effects such as nausea, vomiting, migraines, and sleep disturbances are common, and rare but serious risks include potential damage to the pancreas. Additionally, the weight-loss effect is not universal—some patients do not respond to the medication. The benefits also only persist as long as the drug is taken, often necessitating lifelong treatment.
Cost remains a significant barrier, with prices in the United States exceeding $1,000 per month and around 300 euros in France. Currently, these drugs are only available as injections, though pharmaceutical companies are developing oral versions that have shown promise in early trials.
Health agencies stress that these drugs should only be prescribed to individuals with obesity or overweight for whom traditional methods have failed. France’s ANSM medications authority has warned against using the drugs for aesthetic weight loss, cautioning that inappropriate use could expose patients to serious adverse effects.
Looking ahead, researchers are optimistic about the future of weight-loss drugs. Steven O’Rahilly from Cambridge University predicts a rapid evolution toward more effective, safer, and more affordable treatments. Early results for Novo Nordisk’s experimental drug amycretin suggest even greater efficacy than current GLP-1 drugs.
There is also growing interest in the potential benefits of GLP-1 drugs beyond obesity, including possible positive effects on dementia and addiction, though it remains unclear whether these benefits are direct or linked to improvements in obesity or diabetes.
Disclaimer:
The information in this article is intended for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider regarding any medical condition or treatment options. Side effects and efficacy may vary among individuals. The use of weight-loss drugs should only be undertaken under the supervision of a qualified healthcare professional.
